FY 2023 Financial Results Briefing
Wednesday, May 31, 2023
Linical Co., Ltd.
Kazuhiro Hatano, President and CEO
TSE Prime 2183
Agenda
- Company Overview
- Financial Results for FY ended March 2023
- Forecasts of FY ending March 2024
- Management Strategy
- Strengthening of Profitability
- Strengthening of Governance
2
Our global network
The Americas
United States★
Canada★
Preferred providers in
Latin & South America
- Office/employee locations
Current 18 countries and regions
Germany ★
United Kingdom★
Netherlands★
Czech Republic★
Spain★
Sweden★
Asia
Japan★
China★
South Korea★
Taiwan★
Singapore★
Preferred providers in
Australia
Europe
France★ | Slovakia | |
Italy★ | Portugal | |
Hungary★ | Austria | |
Poland★ | Belgium | |
Romania★ | Switzerland | |
Preferred providers in Scandinavia, Eastern Europe & South Africa
3
The Three Businesses of Linical
- We specialize in clinical development and cover the entire process from the innovative drug development stage through to the new drug development and approval stages.
Innovative drug
development
process
Basic research | Application to | Clinical trials | Post-marketing | |
(2 to 3 years) to | New drug | surveillance and | ||
start a new | phases I to III | |||
non-clinical trials | application | clinical trials | ||
drug trial | (3 to 7 years) | |||
(3 to 5 years) | (4 to 10 years) | |||
The three
businesses of
Linical
CRO business | Contract Medical Affairs | |
From 2005 | From 2011 | |
Innovative Drug | ||
● Market analysis ● Handling of pharmaceutical affairs |
Development Business● Development strategy planning ● Partnering support
From 2016
- We have developed three businesses centered on CRO business.
• Contract Medical Affairs business: | We support post- | marketing clinical research and marketing activities |
- Innovative Drug Development Business :We provide consulting services that give total support for a wide range of pharmaceutical development activities including market analysis, the formulation of pharmaceutical affairs and development strategies, the selection of marketing partners, and the conclusion of contracts.
We Achieved Our Highest Ever Sales for the Second Consecutive Year
Sales and Operating Income since Establishment (Billions of Yen) | April 2018 | (Operating Profit) | |||||||
12.5 | 5 | ||||||||
Net Sales | Operating Profit | U.S. CRO Accelovance | |||||||
(Net sales) | Acquisition | 11.5 | |||||||
November 2014 | 11.3 | 10.9 | 4 | ||||||
10 | |||||||||
European CRO | 10.3 | ||||||||
Acquisition of Nuvisan | 9.1 | ||||||||
March 2013 | January 2014 | 8.3 | 3 | ||||||
7.7 | |||||||||
October 2008 | First Section of | Korea CRO P-Pro | |||||||
the Tokyo Stock | Acquisition | ||||||||
5 | Mothers Listed | Exchange | 2 | ||||||
4.9 | COVID-19 | ||||||||
June 2005 | |||||||||
Establishment | 3.6 | 3.7 | 1 | ||||||
3.1 |
2.0 | 2.4 | 2.5 | |
0.1 | 1.3 | ||
0.6 | 0 | ||
(Fiscal year) 2006/3 2007/3 2008/3 2009/3 2010/3 2011/3 2012/3 2013/3 2014/3 2015/3 2016/3 2017/3 2018/3 2019/3 2020/3 2021/3 2022/3 2023/3
We achieved our highest ever sales for the second consecutive year. Operating profit also | |
recovered, bringing the operating margin to a level in excess of 10%. | 5 |